CIK 0001829802 · <br>Emerging growth company
Faeth Therapeutics, Inc.
Sign in to watch- Ticker
- FTH
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 512-200-2982
- Business address
- 701 TILLERY STREET #12 #1010, AUSTIN, TX, 78702
- Former names
- Sensei Biotherapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-17 | Parikh Anand Kiran President and CEO | Grant or award · Series B Preferred Stock | +761.43 | 761,428 | ||
| 2026-02-17 | Parikh Anand Kiran President and CEO | Grant or award · Employee Stock Option (right to buy) | +12,320 | 12,320 | ||
| 2026-02-17 | Parikh Anand Kiran President and CEO | Grant or award · Employee Stock Option (right to buy) | +136,884 | 136,884 | ||
| 2026-02-17 | Parikh Anand Kiran Chief Operating Officer | Grant or award · Series B Preferred Stock | +809,822 | 809,822 | ||
| 2026-02-17 | Parikh Anand Kiran Chief Operating Officer | Grant or award · Employee Stock Option (right to buy) | +92,533 | 92,533 | ||
| 2026-02-17 | Parikh Anand Kiran Chief Operating Officer | Grant or award · Employee Stock Option (right to buy) | +56,673 | 56,673 | ||
| 2026-02-13 | Donenberg Phillip B. Director | Grant or award · Stock Option (right to buy) | +1,900 | 1,900 | ||
| 2025-12-09 | Cambrian BioPharma Inc 10% owner | Sale | −3,105 | $8.59 | $27K | 158,254 |
| 2025-12-09 | Cambrian BioPharma Inc 10% owner | Sale | −2,666 | $7.95 | $21K | 155,588 |
| 2025-12-09 | Cambrian BioPharma Inc 10% owner | Option exercise | +395 | $6.40 | $3K | 155,983 |
| 2025-12-09 | Cambrian BioPharma Inc 10% owner | Sale | −395 | $8.04 | $3K | 155,588 |
| 2025-12-09 | Cambrian BioPharma Inc 10% owner | Sale | −446 | $7.92 | $4K | 155,142 |
| 2025-12-09 | Cambrian BioPharma Inc 10% owner | Option exercise · Stock Option (Right to Buy) | −395 | 0 | ||
| 2025-12-09 | Peyer James 10% owner | Sale | −2,666 | $7.95 | $21K | 155,588 |
| 2025-12-09 | Peyer James 10% owner | Option exercise | +395 | $6.40 | $3K | 155,983 |
| 2025-12-09 | Peyer James 10% owner | Sale | −395 | $8.04 | $3K | 155,588 |
| 2025-12-09 | Peyer James 10% owner | Sale | −446 | $7.92 | $4K | 155,142 |
| 2025-12-09 | Peyer James 10% owner | Option exercise · Stock Option (Right to Buy) | −395 | 0 | ||
| 2025-12-08 | Peyer James 10% owner | Sale | −3,105 | $8.59 | $27K | 158,254 |
| 2025-12-05 | Cambrian BioPharma Inc 10% owner | Sale | −14,508 | $11.40 | $165K | 163,146 |
Page 6 of 12 · 238 trades